TABLE 3.
Number of cells and sequences obtained for each subset and participant
| Group and SCOPE PID | No. of sequences and CD4+ T-cells used for analysis |
|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NV |
SCM |
CM |
TM |
EM |
TD |
|||||||||||||
| Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | Cells analyzed | Defective | Intact | |
| Early | ||||||||||||||||||
| 2647 | 2,008,627 | 20 | 1 | 104,356 | 2 | 0 | 606,738 | 49 | 2 | 488,060 | 35 | 0 | 557,995 | 46 | 2 | 355,176 | 38 | 1 |
| 2531 | 846,802 | 2 | 1 | 505,614 | 11 | 1 | 845,044 | 26 | 0 | 369,349 | 33 | 1 | 241,380 | 37 | 0 | 589,001 | 33 | 2 |
| 2664 | 2,460,392 | 12 | 0 | NA | NA | NA | 1,124,804 | 42 | 0 | 750,758 | 24 | 1 | 285,373 | 56 | 0 | 350,372 | 39 | 0 |
| 2606 | 2,377,831 | NA | NA | NA | NA | NA | 3,074,632 | 10 | 0 | 2,709,673 | 34 | 1 | 1,419,446 | 21 | 0 | 794,481 | 2 | 0 |
| 2454 | 944,567 | 7 | 0 | NA | NA | NA | 822,853 | 34 | 0 | 606,953 | 42 | 1 | 370,087 | 26 | 0 | NA | NA | NA |
| 2661 | 1,312,753 | NA | NA | NA | NA | NA | 1,005,587 | 1 | 0 | 978,764 | 0 | 1 | 1,125,278 | 9 | 21 | NA | NA | NA |
| Late | ||||||||||||||||||
| 1408 | 2,008,675 | 1 | 0 | NA | NA | NA | 666,109 | 39 | 0 | 288,519 | 46 | 0 | 196,068 | 20 | 6 | 231,663 | 8 | 0 |
| 3632 | 1,972,938 | 6 | 2 | 155,591 | 3 | 0 | 844,189 | 14 | 0 | 1,200,376 | 31 | 2 | 409,945 | 35 | 0 | 677,269 | 3 | 0 |
| 1756 | 2,860,172 | NA | NA | 131,518 | 2 | 0 | 1,024,396 | 15 | 0 | 997,705 | 19 | 15 | 679,114 | 18 | 22 | 175,675 | NA | NA |
| 2274 | 342,384 | NA | NA | NA | NA | NA | 1,107,273 | 25 | 1 | 825,005 | 43 | 0 | 350,637 | 25 | 10 | NA | NA | NA |
| 2208 | 1,010,249 | 36 | 0 | NA | NA | NA | 367,777 | 35 | 1 | 419,586 | 31 | 2 | 267,978 | 34 | 0 | 248,955 | NA | NA |